Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

Ruth M. O'Regan, MD
Published: Tuesday, May 16, 2017



Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Checkpoint inhibitors are garnering a lot of interest in HER2-positive breast cancer, specifically in the estrogen receptor (ER)-negative population, says O’Regan.

ER-positive/HER2-positive cancers are very heterogeneous, some of which have a luminal A phenotype. O’Regan says that there might be promise in treating these patients with HER2-targeted therapy, instead of chemotherapy.
 


Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Checkpoint inhibitors are garnering a lot of interest in HER2-positive breast cancer, specifically in the estrogen receptor (ER)-negative population, says O’Regan.

ER-positive/HER2-positive cancers are very heterogeneous, some of which have a luminal A phenotype. O’Regan says that there might be promise in treating these patients with HER2-targeted therapy, instead of chemotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x